Lion Point Capital, LP Durect Corp Transaction History

Lion Point Capital, LP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$0.43 - $5.9 $539,748 - $7.41 Million	1,255,230 Added 9.63%	14,283,066 $7.85 Million
Q2 2022 Aug 15, 2022	SELL	$0.38 - $0.64 $934,103 - $1.57 Million	-2,458,168 Reduced 15.87%	13,027,836 $7.25 Million
Q3 2021 Nov 15, 2021	BUY	$1.21 - $1.61 $214,696 - $285,670	177,435 Added 1.16%	15,486,004 $19.8 Million
Q1 2021 May 19, 2021	BUY	$1.86 - $2.87 $4.57 Million - $7.05 Million	2,458,168 Added 19.13%	15,308,569 $30.3 Million
Q1 2021 May 17, 2021	SELL	$1.86 - $2.87 $9.08 Million - $14 Million	-4,880,279 Reduced 27.52%	12,850,401 $25.4 Million
Q3 2020 Nov 16, 2020	SELL	$1.6 - $2.35 $1.38 Million - $2.03 Million	-862,623 Reduced 4.64%	17,730,680 $30.3 Million
Q2 2020 Aug 14, 2020	SELL	$1.33 - $2.76 $1.2 Million - $2.48 Million	-899,156 Reduced 4.61%	18,593,303 $43.1 Million
Q1 2020 May 15, 2020	BUY	$0.97 - $2.85 $720,185 - $2.12 Million	742,459 Added 3.96%	19,492,459 $30.2 Million
Q2 2019 Aug 14, 2019	BUY	$0.51 - $0.86 $9.56 Million - $16.1 Million	18,750,000 New	18,750,000 $12.2 Million

593K

Ticker DRRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 227,794,000
Market Cap $171M
Description
DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops larsucosterol (DUR-928), an endogeno...

Get notified when there are updates to the investment portfolio of Lion Point Capital, LP, based on Form 13F filings with the SEC.

Stay updated on Lion Point Capital, LP with notifications on news.